Twist Bioscience Announces Technology Early Access of Enhanced Whole Genome Sequencing Solution at AGBT
08 February 2023 - 12:00AM
Business Wire
Additional sequencing applications and
reference standards to be highlighted at the conference
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced technology early
access of the Twist enhanced Whole Genome Sequencing (eWGS)
solution focused on non-human genomics applications, at the
Advances in Genome Biology and Technology (AGBT) 2023 General
Meeting in Hollywood, Florida. eWGS is a novel solution that
enables researchers to obtain simultaneous low-pass whole genome
data together with deep coverage of selected regions, in a
high-throughput and cost-effective workflow.
“In agricultural genomics, researchers constantly have to make a
tradeoff between cost and insight. Deep sequencing across entire
genomes is cost prohibitive, forcing researchers to turn to less
costly approaches like genotyping by sequencing, microarrays, or
low-pass WGS. These methods impose limits on the resolution,
accuracy, or flexibility of experiments,” said Emily M. Leproust,
Ph.D., CEO and co-founder of Twist Bioscience. “With our eWGS
solution, researchers can now get all the information they need
without compromising on cost or data, enabling our customers to
push new boundaries in trait selection, breeding and other
applications.”
The eWGS workflow starts with a modified Twist 96-plex library
preparation kit that prepares 96 samples for sequencing in a single
tube. This is followed by single-tube 96-plex enrichment on an
aliquot of the library, using a customized panel to further enrich
targets requiring more coverage. The original and enriched
libraries are then combined into a single sequencer-ready pool that
has both low whole genome coverage between 0.5x and 4x as well as
high target-specific coverage. Researchers can tune the
differential in coverage between low-pass and high-pass sites to
fit their needs. Preparing and enriching 96 samples at a time for
sequencing in a single pool can enable a high-throughput workflow
and may reduce costs by using less materials and resources.
In addition to the technology early access of eWGS, Twist will
have three posters highlighting applications of Twist’s
next-generation sequencing (NGS) tools and reference standards
available for viewing at the conference.
Details of the posters are as follows:
Poster: Use of synthetic CNV fragments to mimic copy number
alterations for ctDNA reference standards Time: Tuesday, February
7, 1:30 – 3:30 PM ET
Poster: An RNA exome panel used to enrich transcript variants
using cDNA libraries Time: Tuesday, February 7, 1:30 – 3:30 PM
ET
Poster: Methylation Controls to detect for methylation level
quantification in the Twist Targeted Methylation Sequencing
workflow Time: Wednesday, February 8, 4:45 – 6:10 PM ET
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the anticipated
capabilities of the eWGS solution to enable researchers to obtain
simultaneous low-pass whole genome data together with deep coverage
of selected regions. Forward-looking statements involve known and
unknown risks, uncertainties, and other important factors that may
cause Twist Bioscience’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the risks and uncertainties relating to COVID-19; the
ability to attract new customers and retain and grow sales from
existing customers; risks and uncertainties of rapidly changing
technologies and extensive competition in synthetic biology that
could make the products Twist Bioscience is developing obsolete or
non-competitive; uncertainties of the retention of significant
customers; the ability of Twist Bioscience to successfully
integrate acquired companies, including Abveris, and to achieve
expected benefits from acquisitions; supply chain and other
disruptions caused by the COVID-19 pandemic or otherwise; risks of
third party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist Bioscience’s patents or
proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies.
For a description of the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Annual Report on Form 10-K
filed with the Securities and Exchange Commission on November 28,
2022 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230207005576/en/
For Twist Bioscience: Angela Bitting SVP, Corporate
Affairs 925- 202-6211 abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024